The Role of Molecular Testing in the Treatment of AML


Other Resources

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on whether the FLT3 test may be applied in newly diagnosed acute myelogenous leukemia (AML)

Published:12 December 2018

The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.

© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.